Skip to main content
OpenTrials

Clinical trial condition

Dense Deposit Disease

Explore clinical trials studying Dense Deposit Disease. Study availability and eligibility vary by location and protocol.

9 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Dense Deposit Disease trial results

Completed

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127

Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, C3G, +19 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Academic Medical Research Institute Los Angeles, California, United States
  • Keck School of Medicine, University of Southern California Los Angeles, California, United States
  • Ronald Reagan UCLA Medical Center (01035) Los Angeles, California, United States
View all 125 locations
View Trial Details
Completed

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619

Conditions
Autoimmune Diseases, C3 Glomerulonephritis, Connective Tissue Diseases, +18 more
Locations
  • Stanford University Stanford, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • HealthONE Physician Care, Rocky Mountain Hospital for Children Denver, Colorado, United States
  • Washington Nephrology Associates Washington D.C., District of Columbia, United States
View all 17 locations
View Trial Details
Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236

Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, Dense Deposit Disease, +10 more
Locations
  • Clinical Study Site Aurora, Colorado, United States
  • Clinical Study Site Lawrenceville, Georgia, United States
  • Clinical Study Site Iowa City, Iowa, United States
  • Clinical Study Site Baltimore, Maryland, United States
View Trial Details
Active, Not Recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531

Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, C3G, +19 more
Locations
  • Academic Medical Research Institute (01034) Los Angeles, California, United States
  • Children's Hospital Colorado (01037) Aurora, Colorado, United States
  • University of Florida, Department of Pediatric Nephrology (01010) Gainsville, Florida, United States
  • Emory Investigational Drug Service (01021) Atlanta, Georgia, United States
View all 47 locations
View Trial Details

Related conditions